Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Days Inventory for the quarter that ended in Mar. 2026 was 167.29.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.93.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Change In Inventory Related Terms
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Change In Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Change In Inventory Chart
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£122 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of E£122 Mil mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a Change In Inventory of E£122 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Change In Inventory too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current Change In Inventory is E£122 Mil. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Change In Inventory compare to ZTS and UTHR?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' Change In Inventory of E£122 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current Change In Inventory is E£122 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Significantly Overvalued. The stock's GF Value™ is E£4.21, compared to a current price of E£6.65 — trading 58% above its estimated fair value. The current Change In Inventory is E£122 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 88/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current Change In Inventory is E£122 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£6.65 is trading 58% above its estimated GF Value™ of E£4.21.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Significantly Overvalued.
Key valuation signals for CAI:RMDA:
Change In Inventory: E£122 Mil
GF Value™: E£4.21 vs. price of E£6.65 (58% above fair value)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
88GF Score
Get the complete analysis for CAI:RMDA
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
